News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The approval was driven by data from the Phase III TULIP-SC trial
Growth was broad-based across segments
Move to accelerate cancer care expansion across India
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
